This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Attorney Docket No.: 16305-008030

As the below named inventor(s), I/we declare that:

PTO/SB/01A (10-00)

Client Ref. No.:

Approved for use

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

This declaration is directed to:					
		The attached application, or			
	\boxtimes	Application No. <u>09/896,812</u> , filed on <u>June 29, 2001</u> ,			
		as amended on (if applicable);			
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claime for which a patent is sought;					
I/we have reviewed and understand the contents of the above-identified application, including to claims, as amended by any amendment specifically referred to above;					
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all informati known to me/us to be material to patentability as defined in 37 CFR 1.56, including material informati which became available between the filing date of the prior application and the National or Pointernational filing date of the continuation-in-part application, if applicable; and					
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.					
	•				
FULL NAME OF INVE	NTOR(S)				
FULL NAME OF INVE	NTOR(S)	124 24			
FULL NAME OF INVE	NTOR(S)	Madden Date: Du. 18 2001 Waldy Citizen of: Canada			
FULL NAME OF INVE	NTOR(S)	Madden Date: Du. 18 2001 Muddy Citizen of: Canada			
FULL NAME OF INVE Inventor one	NTOR(S)	Date: Duc. 18 2001 William Citizen of: Canada Date: Dec. 12, 2001 Citizen of: Canada			
FULL NAME OF INVE Inventor one	omas D. M	Date: Dec 12 2001 Citizen of: Canada Date: Dec 12 2001 Citizen of: Canada Date: Dec 101 2001			
FULL NAME OF INVE Inventor one	omas D. Monas D. Mona	Date: Duc. 18 2001 William Citizen of: Canada Date: Dec. 12, 2001 Citizen of: Canada Date: Dec. 10th 2001			
FULL NAME OF INVE	omas D. Monas D. Monas C. Serr	Date: Du. 18 2001 Muddly Citizen of: Canada Date: Dec. 12, 2001 Citizen of: Canada Date: Dec. 10th 2001 Citizen of: Canada			

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1242111 v1

Please type a plus sign (+) inside this box

POWER OF ATTORNEY OR

PTO/SB/81 (02-01) Approved for use through 10/31/2002, OMB 0651-0035

LIPOSOMAL ANTINEOPLASTIC

09/896,812

June 29, 2001

Thomas D. Madden

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number. Application Number

First Named Inventor

Filing Date

Title **AUTHORIZATION OF AGENT** DRUGS AND USES THEREOF 1615 **Group Art Unit** Unassigned **Examiner Name** 16303-008030 Attorney Docket Number I hereby appoint: Place Customer □ Practitioners at Customer Number 20350 Number Bar Code Label here ☐ Practitioner(s) named below: Name **Registration Number** as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith. Please change the correspondence address for the above-identified application to: ☐ The above-mentioned Customer Number Practitioners at Customer Number Firm or Individual Name Address Address State ZIP City Country Telephone I am the: Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). SIGNATURE of Applicant or Assignee of Record Name Signature NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*. *Total of 1 form is submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the Individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1267279 v1

PTO/SB/96 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Attorney Docket No. 16303-008030

STATEMENT UNDER 37 CFR 3.73(b)				
Applicant/Patent Owner. Thomas D. Madden, Sean C. Semple and Quet F. Ahkong				
A cultivation No. (Debugging and Control of the Con				
Application No./Patent No.: 09/896,812 Filed/Issue Date: June 29, 2001				
Entitled: LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF				
Inex Pharmaceuticals Corporation , a corporation , a corporation (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)				
states that it is:				
1. the assignee of the entire right, title, and interest; or				
2. an assignee of an undivided part interest				
in the patent application/patent identified above by virtue of either:				
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
OR				
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:				
1. From:				
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
2. From: To :				
The document was recorded in the United States Patent and Trademark Office at				
Reel, Frame, or for which a copy thereof is attached.				
3. From:				
The document was recorded in the United States Patent and Trademark Office at				
Reel, Frame, or for which a copy thereof is attached.				
Additional documents in the chain of title are listed on a supplemental sheet.				
☐ Copies of assignments or other documents in the chain of title are attached.				
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]				
The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.				
4/13/01 TB MacRuni				
Date Signature				
דאירת "ם נזיכענעץ דאיטיסי טוגע אומדווערן				
Typed or printed name				
Title				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Attorney Docket No.: 16303-008030

ASSIGNMENT OF PATENT APPLICATION

JOINT

WHEREAS, Thomas D. Madden, of 2714 West 31st Avenue, Vancouver, B.C., Canada V6L 2A1, Canada; Sean C. Semple, of 2201 – 588 Broughton Street, Vancouver, B.C., Canada V6G 3E3, Canada; Quet F. Ahkong, of 8588, 143rd Street, Surrey, B.C., Canada V3W 0N9, Canada; hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention:

LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES

THEREOF

Filing Date:

June 29, 2001

Application No.:

09/896,812; and

WHEREAS, Inex Pharmaceuticals Corporation, located at 100-8900 Glenlyon Parkway, Glenlyon Business Park, Burnaby, B.C., Canada V5J 5J8, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on the same:

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

Assignors hereby authorize and request Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834, to insert herein above the application number and filing date of said application when known.



Assignment Attorney Docket No.: 16303-008030 Page 2

	F, Assignors have signed their names on the dates ind
ated: Dec. 13th 2011	Thomas D. Madden
	· · · ·
GNATURE WITNESSED BY:	
) Dated: Dec 13th 2001	maia Toffen
Dated: <u>) = [], 2 = []</u>	fronte oredongall
ated: De C 12, 200/	Sean C. Schmile
IGNATURE WITNESSED BY:	
) Dated: Dec. 12, 200/	function Medangul
2) Dated: Pec 12, doc4	Alega Giscolo
Dec 10th 2011	Q. F. Ahkong Quet F. Ahkong
IGNATURE WITNESSED BY:	
1) Dated: <u>Dec. 10/2.50</u> /	Same Medongall
2) Dated: Dec 10/12/2001 DEC 10/2001 F 1266727 v1	M. Flenandes
	COPY

Please type a plus sign (+) inside this box

 $\rightarrow \Box$

PTO/SB/82 (10-00)
Approved for use through 10/31/2002. OMB 0651-0035
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	09/896,812	
	Filing Date	June 29, 2001	
REVOCATION OF POWER OF ATTORNEY OR	First Named Inventor	Thomas D. Madden	•
AUTHORIZATION OF AGENT	Group Art Unit	1615	
•	Examiner Name	Gollamudi S. Kishore	_
.	Attorney Docket Number	16303-008030	
	·		

I hereby revidentified ap		ous powers o	f attorney or	r authoriza	tior	ns of agent o	given i	n the abo	ve-
X A Pov	A Power of Attorney or Authorization of Agent is submitted herewith.								
OR									
Pleas	e change the	e corresponde	ence addres	s for the a	bov	e-identified	applic	ation to:	
					•			•	
☑ Customer Number — → 00500									
OR							<i>:</i>		
Firm <i>or</i> Individua	il Name						•		
Address									
Address		`				·			
City			· · · · · · · · · · · · · · · · · · ·	<u></u>					
Country	_			Stat	е		ZIP		;
Telephone		Fax							
I am the:	I am the:								
Паррііс	∏Applicant/Inventor.								
<u>.</u>									
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)									
SIGNATURE of Applicant or Assignee of Record									
Name	Jeff Charpentier – VP Finance & CFO								
Signature Signature									
Date	te September 15, 2003								
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.									
*Total of	forms are s								

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

VIA FACSIMILE

PTO/SB/81 (10-00)
Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are

ELECTION AND POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

re required to respond to a condition of	thornason unless it displays a valid Onlo control number				
Application Number	09/896,812				
Filing Date	June 29, 2001				
First Named Inventor	Thomas D. Madden				
Group Art Unit	1615				
Examiner Name	Gollamudi S. Kishore				
Attorney Docket Number	480208.408				

		Name and the same	-				
I hereby appoi	ereby appoint:			Customer Number			
Practitioners	s at See	ed IP Law Group PLLC		 →			
OR OR				•	00500	(0)	
Practitioner(s) name	ed below:		÷			
		Name	<u> </u>	Registration N	umber		
						·	
		or agent(s) to prosecute the application	identifie	d above, and to trans	sact all business i	n the Patent and	
Trademark Office	ce conn	nected therewith.		·			
		respondence address for the above-ide	entified a	pplication to:			
X The above-m	entione	ed Customer Number.					
Firm or Individual N	lame						
Address							
Address							
City			State		ZIP		
Country	•				·	· · · · · · · · · · · · · · · · · · ·	
Telephone			Fax	180		•	
I am the:			•	·			
Applicant/Ir	nventor.	•					
_ `	Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). X As assignee of record of the entire interest I/we hereby elect, under 37 C.F.R. § 3.71, to prosecute the application to the					application to the	
X As assigne exclusion of			leut, una		to prosecute are	application to the	
SIGNATURE of Applicant or Assignee of Record							
Name Je	eff Char	rpentier - VP Finance & CFO					
Signature	1						
Date S	epten/b	per 15, 2003					
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.							
	*Total of forms are submitted.						

This collection of Information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



 VIA FACSIMILE PTO/SB/96 (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, 'no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: Thomas D. Madden et al.
Application No./Patent No.: 09/896,812 Filed/Issue Date: June 29, 2001
Entitled: LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF
Inex Pharmaceuticals Corporation , a corporation (Name of Assignee) a corporation (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:
1. X the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is%
in the patent application/patent identified above by virtue of either:
 An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012527, Frame 0129, or for which a copy thereof is attached. OR
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:
1. From:
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
2. From: To:
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
3. From: To:
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.
Copies of assignments or other documents in the chain of title noted in B above are attached.
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
September 15, 2003 Jeff Charpentier
Date Typed or printed name
604.419.3200
Telephone Number Signature
VP Finance & CFO Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.